Previous 10 | Next 10 |
FARMINGTON HILLS, Mich., June 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that Victor H. Gonz...
FARMINGTON HILLS, Mich., June 12, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that a presentation...
2023-05-15 09:24:03 ET Ocuphire Pharma press release ( NASDAQ: OCUP ): Q1 GAAP EPS of -$0.28 misses by $0.13 . Revenue of $1.75M misses by $1.19M . For further details see: Ocuphire Pharma GAAP EPS of -$0.28 misses by $0.13, revenue of $1.75M misses by $1...
End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy (DR) PDUFA date for Nyxol First Indication in Reversal of Pharmacologically-Induced Mydriasis (RM) Set for September 28, 2023; Nyxol Development and Commerc...
FARMINGTON HILLS, Mich., May 02, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations featur...
PDUFA Date of September 28, 2023 Set for Nyxol ® in its First Indication, Reversal of Pharmacologically-induced Mydriasis (RM); $10 Million Milestone Linked to Approval Oral APX3330 End of Phase 2 Meeting with FDA Anticipated in 2023 to Align on Regulatory Path for Diab...
2023-04-21 13:53:45 ET Gainers: Presto Automation ( PRST ) +49% . CBL International Limited ( BANL ) +34% . EyePoint Pharmaceuticals EYPT +31% . Asset Entities ( ASST ) +25% . ContextLogic ( WISH ) +24% . Mullen Automotive ( MU...
2023-04-21 10:03:36 ET Gainers: EyePoint Pharmaceuticals ( EYPT ) +19% . Tenaya Therapeutics ( TNYA ) +21% . Community Health Systems ( CYH ) +11% . NovaBay Pharmaceuticals ( NBY ) +11% . Aziyo Biologics ( AZYO ) +8% . Loser...
2023-04-21 08:50:22 ET Ocuphire Pharma ( NASDAQ: OCUP ) has appointed Rick Rodgers as Interim Chief Executive Officer and President, succeeding Mina Sooch. Ocuphire has retained an executive search firm to assist in identifying a permanent CEO. He has se...
FARMINGTON HILLS, Mich., April 21, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it has appoin...
News, Short Squeeze, Breakout and More Instantly...
Ocuphire Pharma Inc Com Company Name:
OCUP Stock Symbol:
NASDAQ Market:
Ocuphire Pharma Inc Com Website:
CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42 nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (N...
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today anno...
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial r...